36 KB146 KB21 KB192920262008Černelč, PeterKabaklić, Amelaštevilka:16 straniletnik:77str. I-81-I-86ISSN:1318-0347COBISSID:24129497URN:URN:NBN:SI:doc-74NMUHJCslSlovensko zdravniško društvoZdravniški vestnikBeta 2-MicroglobulinBeta 2-mikroglobuliniDrug TherapyhematologijaMelfalanMelphalanMultiple MyelomaMultipli mielomplazmocitomPreživetje, analizaSurvival AnalysisTalidomidThalidomidetherapyzdravljenjeOcena uspešnosti enajstletnega zdravljenja starejših bolnikov z diseminiranim plazmocitomom| Evaluation of treatment for elderly patients with multiple myeloma|Background In this retrospective study we have evaluated the effectiveness of different ways of treatment for elderly patients with multiple myeloma and we have compared our results with already published clinical studies. Methods Theprimary goal of our study was to establish the overall survival of 120 elderly patients with multiple myeloma which was defined as timeframe from theonset of the diagnosis up to the point of last check-up or death. In the first part of the study we compared the survival of patients treated with alceran (melphalan) and prednisone or other medications without thalidomide, with survival of patients being treated with thalidomide. The results of our study were compared to findings in other published clinical studies. In the second part we continued to compare the median overall survival of our patients with expected survival staged with international prognostic factors (Durie-Salmon staging system and International staging system ISS). The medialoverall survival was evaluated using the Kaplan-Meier method. Results Median overall survival times were 67.1 months for all 120 elderly patients with multiple myeloma, 33.4 months for patients treated with alceran and prednisone (AP) or other medications (DZ) without thalidomide (AP+DZ), 112.7 months for patients treated with AP, thalidomide and other medications (AP+DZ+T), 30.2 months for patients treated with other medications but withoutthalidomide (DZ) and 78.7 months for patients treated only with thalidomide or with thalidomide and other medications (T+DZ). Treatment with AP+DZ+T was asociated with significantly better survival than was AP+DZ (p = 0.0003). Treatment T+DZ was also asociated with significantly better survival than was DZ (p < 0.0001). The results of median survival times staged by Durie-Salmon staging system and International staging system ISS were not representative because of smal number of observed patients (n = 120 i.e. 81). (Abstract truncated at 2000 characters)TEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of SloveniaSlovensko zdravniško društvo